What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to formally report and make available Regeneron's financial and operating results for the fourth quarter and the full year ended December 31, 2014. It includes a press release with these details.

Where can I find the actual financial results and operational details?

The specific financial results and operational details are contained within the press release dated February 10, 2015, which is provided as Exhibit 99.1 to this 8-K filing.

What does it mean that the information is 'furnished' and not 'filed'?

When information is 'furnished' as opposed to 'filed' under Section 18 of the Securities Exchange Act of 1934, it generally means the company is providing the information for public disclosure but is not subject to the same level of liability for misstatements or omissions under that specific section of the law. However, it is still considered material information for investors.

What time period do the results cover?

The results reported in this filing cover the fourth quarter and the full fiscal year that ended on December 31, 2014.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 10, 2015, to report its fourth quarter and full year 2014 financial and operating results, released on February 10, 2015. While the 8-K itself is brief, it serves as a filing vehicle for a press release containing detailed financial performance and operational updates for the period ending December 31, 2014. Investors should refer to the furnished press release (Exhibit 99.1) for comprehensive information regarding the company's performance, including key metrics, product sales, pipeline developments, and forward-looking statements. The 8-K filing is standard procedure for disseminating such crucial earnings information to the market.

Key Highlights

1Filing of Q4 and Full Year 2014 financial and operating results via press release (Exhibit 99.1).
2Press release dated February 10, 2015, contains the detailed results.
3The 8-K serves as a formal notification and filing mechanism for the earnings announcement.
4Information in the press release is furnished, not deemed 'filed' under Section 18 of the Exchange Act, limiting certain legal liabilities.
5Key financial and operational metrics for the fourth quarter and full year 2014 are available in the press release.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 10, 2015)

Summary

Key Highlights

Frequently Asked Questions